Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.63 USD

1.63
511,514

-0.04 (-2.40%)

Updated May 17, 2024 04:00 PM ET

After-Market: $1.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.

Accuray's New CyberKnife S7 System to Boost Patient Care

by Zacks Equity Research

Accuray's (ARAY) newly launched CyberKnife S7 System will enable clinicians to provide best possible care to their patients through new capabilities.

Here's Why You Should Add Accuray to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.

Why Is Accuray (ARAY) Down 9.2% Since Last Earnings Report?

by Zacks Equity Research

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

6 Stocks to Benefit From the 'New Normal'

by Zacks Equity Research

The coronavirus-led 'new normal' has altered several businesses. Here are three sectors that will see a boom in the near future.

Delivery Robots Making an Impression Amid Coronavirus Pandemic

by Zacks Equity Research

Since the coronavirus outbreak, robots have filled up several job vacancies caused by social distancing orders. Here are five robotics and related stocks investors should closely watch.

How Accuray (ARAY) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Accuray (ARAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Will Accuray (ARAY) Gain on Rising Earnings Estimates?

by Zacks Equity Research

Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

What Makes Accuray (ARAY) a New Strong Buy Stock

by Zacks Equity Research

Accuray (ARAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nitish Marwah headshot

New Strong Buy Stocks for May 1st

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.

Accuray (ARAY) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Accuray (ARAY) delivered earnings and revenue surprises of 200.00% and 3.21%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Sriparna Ghosal headshot

Here's Why You Should Retain Accuray in Your Portfolio

by Sriparna Ghosal

Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.

Why You Should Invest in Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.

Here's Why You Should Invest in DaVita (DVA) Stock Right Now

by Zacks Equity Research

DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.

Here's Why You Should Hold On to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) expects to witness foreign exchange headwinds in 2020.

    Here's Why You Should Hold On to Inogen (INGN) Stock for Now

    by Zacks Equity Research

    Inogen (INGN) expects to report a loss per share in the first quarter of 2020.

    Here's Why You Should Retain Merit Medical (MMSI) Stock Now

    by Zacks Equity Research

    Merit Medical (MMSI) continues to benefit from growing product pipeline, strong R&D focus and strategic acquisitions.

      Here's Why Investors Should Buy Masimo (MASI) Stock Now

      by Zacks Equity Research

      Masimo (MASI) sees a slew of developments lately.

        Masimo & University Hospitals Unite for Patient Monitoring

        by Zacks Equity Research

        Masimo (MASI) sees a plethora of developments lately.

          PRA Health's New Program to Lend Support to Healthcare System

          by Zacks Equity Research

          PRA Health's (PRAH) COVID-19 Monitoring Program will allow individuals to connect with a healthcare professional remotely while maintaining social distancing.

          Here's Why You Should Hold on to NextGen Healthcare Stock Now

          by Zacks Equity Research

          NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and robust demand for other NextGen solutions.

          Masimo's Latest Buyout to Boost Respiratory Product Spectrum

          by Zacks Equity Research

          Masimo (MASI) expects the transaction to be neutral to 2020 earnings.

          Here's Why You Should Hold Onto Baxter (BAX) Stock for Now

          by Zacks Equity Research

          Baxter (BAX) issues strong guidance for the first quarter of 2020.

          Accuray Enters Oversold Territory

          by Zacks Equity Research

          Accuray has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.